Ignite Creation Date:
2024-07-17 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06487858
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2024-06-20
Brief Title:
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
Sponsor:
BeiGene
Organization:
BeiGene
Study Overview
Official Title:
A Multicenter Open-Label Phase 1a1b Study to Evaluate the Safety and Preliminary Antitumor Activity of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a first-in-human FIH study that will evaluate the safety tolerability pharmacokinetics PK pharmacodynamics and preliminary antitumor activity of BGB-R046 as a single agent and in combination with tislelizumab BGB-A317 in participants with advanced or metastatic immune-sensitive solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None